Research Signal – Source date 2025-07-10
A cell that stops dividing can help protect the body: damaged cells are less likely to multiply and pass on problems. But the stopped cell remains in its tissue, where it may release signals that affect neighbors. Those signals can help coordinate repair in some settings and contribute to disease in others.
A review published July 10, 2025, brings together findings on cellular senescence—the sustained arrest of cells that stop dividing—in development, tissue repair, cancer and disease models. It describes mechanisms that trigger the arrest, along with examples of how senescent cells and their surroundings may shape what happens next. The central puzzle is why a protective brake can also become part of a harmful tissue environment, and whether changing senescent cells can help patients.
A damaged cell reaches a molecular stop
Telomeres are DNA sequences and associated proteins at chromosome ends. They help protect those ends, but repeated cell division can shorten telomeres. Shortened telomeres can trigger a DNA-damage response, as can other persistent damage. The response activates proteins including ATM, ATR, CHK1 and CHK2, which help regulate p53.
The p53 protein can increase production of p21, encoded by the gene CDKN1A. P21 inhibits cyclin-dependent kinases, or CDKs, that help drive the cell cycle. When these kinases are held back, the machinery that advances cell division is disrupted, and the cell can become arrested.
A second route involves p16, produced from the CDKN2A locus. P16 inhibits CDK4 and CDK6, also disrupting the complexes that help a cell progress through division. The review describes these p53–p21 and p16 routes as key ways cells respond to severe stress by stopping the cycle. The arrest can block damaged or precancerous cells from multiplying, helping to suppress tumor formation.
Senescence is more than that internal stop, however. Senescent cells can change their shape and size, and many release a mix of substances known as the senescence-associated secretory phenotype, or SASP. Its components include signaling proteins and enzymes that can influence nearby cells and tissue. Their effects help explain why a cell that no longer divides can still matter.
The cell stops, but its signals keep moving
During repair and regeneration, SASP factors can recruit or activate immune cells that remove senescent cells, as well as progenitor or stem cells that contribute to tissue renewal. In this way, senescent cells can participate in processes that help maintain or repair tissue. Their presence is not automatically a sign that tissue is failing.
In idiopathic pulmonary fibrosis, the review describes evidence from models in which senescent alveolar epithelial type 2 cells release SASP factors that prompt profibrotic responses in nearby macrophages and fibroblasts. Those neighboring cells are part of a tissue environment associated with fibrosis. The review also emphasizes that the molecular link between senescence and fibrosis still needs clarification. The proposed chain from a senescent cell’s signals to a damaging tissue response is an active research question, not a complete account of how the disease develops.
Cancer shows another version of the problem. Senescence can help stop precancerous cells from dividing, but senescence within an established tumor may, in some circumstances, support tumor growth or drug resistance. One proposed explanation is that SASP signals can create an immune-suppressive environment. The review says the mechanisms behind this tumor-promoting effect remain poorly understood. The protective role of arrest before a tumor develops and the possible effects of senescent cells inside an established tumor are different stages of the cancer story.
Stressed organelles can deepen the damage loop
Mitochondria, which help supply energy to cells, and lysosomes, which help break down and recycle cellular material, are both implicated in senescence. The review describes a reinforcing cycle: troubled mitochondria can produce reactive oxygen species (ROS), which can damage mitochondrial DNA and lead to more ROS. Lysosomes in senescent cells may also grow in size and number and show changes to their enzymes, membranes and internal conditions. Lysosomal problems can impair mitochondrial maintenance; excess ROS can then damage lysosomes further.
This feedback matters because it suggests routes for studying how cellular stress persists, not just how the first damage triggers arrest. The review discusses TFEB, a transcription factor involved in regulating mitochondria and lysosomes, and HKDC1, a protein identified as a TFEB target. In experimental work described by the review, TFEB-driven HKDC1 helps stabilize PINK1 on mitochondria, supporting PINK1–Parkin mitophagy—the removal of damaged mitochondria. HKDC1 also contributes to lysosomal repair by helping mitochondria and lysosomes form contacts.
In mice, loss of Hkdc1 worsened mitochondrial and lysosomal impairment, increased DNA damage and accelerated senescence. The pathway gives researchers a way to investigate whether better organelle maintenance can interrupt a stress-amplifying loop. The findings are mechanistic evidence from experimental models; they do not establish a treatment for people.
One regulator can point in opposite directions
The review’s discussion of WTAP offers a tissue-specific example. WTAP is part of a complex that adds a chemical modification called m6A to RNA, which can affect how RNA messages are handled. In findings on skin and human dermal fibroblasts, WTAP levels rose with senescence. Reducing WTAP reversed senescence in those experiments. The proposed chain runs through increased m6A modification and expression of ELF3, which in turn promotes IRF8 expression and senescence-associated signals. In mice, this pathway was linked to worsening skin aging.
A separate line of work in a preosteoblast cell line points the other way. There, WTAP supported m6A modification and stability of SP1 RNA; the resulting SP1 activity promoted BMP2 expression, osteoblast differentiation and inhibition of senescence. The opposite directions are a reason for care when considering a regulator as a target: an intervention that alters WTAP could have different effects in different tissues. The review says more research is needed to clarify its role across tissues and conditions.
Flexible proteins offer a possible organizing clue
The review also observes that many of the senescence-related proteins it discusses are predicted to contain intrinsically disordered regions. These regions do not have one fixed structure; they can remain flexible and adopt different shapes. The authors suggest that this property may help make sense of how proteins from varied functional groups can interact with multiple partners and participate in processes such as modification and regulation.
This is a structural classification of a selected group of proteins, not evidence that flexibility causes senescence. Nor does it show that changing protein disorder would be a useful treatment. Its value here is as a possible organizing idea for investigating how the pathways described in the review connect.
Lung evidence spans mice and an early patient pilot
Two strands of lung-fibrosis evidence in the review answer different questions. In mouse work, increasing YTHDC1 in alveolar epithelial cells reversed senescence and reduced fibrosis. The proposed mechanism involves YTHDC1 helping MRE11 and TOPBP1 work together, supporting ATR activation and DNA repair. This suggests a way that improved repair could delay senescence in that model. It does not show that changing YTHDC1 benefits people with lung fibrosis.
Separately, a small open-label pilot gave dasatinib plus quercetin, drugs described as senolytics because they target senescent cells, to 14 people with stable idiopathic pulmonary fibrosis. Participants showed improvements on physical-function tasks including walking, chair stands and gait speed. Mild-to-moderate adverse effects were reported, including bruising or skin irritation, gastrointestinal discomfort and respiratory symptoms; no severe adverse events occurred in this pilot. The findings are an early observation. Without a comparison group, the study cannot establish that the drugs caused the functional changes or that the treatment works more broadly. The review also describes another small, randomized placebo-controlled safety trial, but the open-label pilot’s functional observations should not be read as proof of efficacy.
The mouse research altered a DNA-repair pathway and examined senescence and fibrosis in an experimental model. The pilot instead tested drugs intended to remove senescent cells in people and recorded functional tasks. Neither resolves exactly how senescent cells contribute to lung fibrosis. These approaches are not interchangeable: one probes a possible mechanism in mice, while the other offers limited early clinical observations about a different intervention.
What more selective senescence treatments could change
If researchers can establish when senescent cells drive damaging signals, and identify a way to target those cells or their effects safely, people with lung fibrosis could eventually benefit from treatments that slow harmful tissue changes while preserving useful repair. The pilot’s task improvements offer a reason to investigate that possibility, but larger controlled studies and a clearer account of the senescence–fibrosis link are needed before patients can know whether senolytic treatment provides a real, lasting benefit. The review presents a research direction, not a proven therapy.
Key Sources
- Primary source: Hallmarks of cellular senescence: biology, mechanisms, regulations.
DOI or Journal Page · Review or Meta-Analysis · 2025-07-10
Keep exploring